{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:12:10Z","timestamp":1792588330652,"version":"4.5.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,11]]},"abstract":"\n Background and objectives<\/jats:title>\n Anemia is an early complication of CKD that is associated with increased morbidity and mortality. Prior data show associations between abnormal mineral metabolism markers and decreased erythropoiesis. However, few studies have investigated elevated fibroblast growth factor 23 as a risk factor for the development of anemia in patients with CKD.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n We conducted a prospective cohort study of 3869 individuals with mild to severe CKD enrolled in the Chronic Renal Insufficiency Cohort Study between 2003 and 2008 and followed through 2013. We hypothesized that elevated baseline fibroblast growth factor 23 levels are associated with prevalent anemia, decline in hemoglobin over time, and development of incident anemia, defined as serum hemoglobin level <13 g\/dl in men, serum hemoglobin level <12 g\/dl in women, or use of erythropoietin stimulating agents.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the 1872 of 3869 individuals who had prevalent anemia at baseline, mean age was 58 (11) years old, and mean eGFR was 39 (13) ml\/min per 1.73 m\n 2<\/jats:sup>\n . Higher levels of fibroblast growth factor 23 were significantly associated with prevalent anemia (odds ratio per 1-SD increase in natural log\u2013transformed fibroblast growth factor 23, 1.39; 95% confidence interval, 1.26 to 1.52), decline in hemoglobin over 4 years, and risk of incident anemia (hazard ratio per 1-SD increase in natural log\u2013transformed fibroblast growth factor 23, 1.13; 95% confidence interval, 1.04 to 1.24; quartile 4 versus quartile 1: hazard ratio, 1.59; 95% confidence interval, 1.19 to 2.11) independent of demographic characteristics, cardiovascular disease risk factors, CKD-specific factors, and other mineral metabolism markers. The results of our prospective analyses remained unchanged after additional adjustment for time-varying eGFR.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Elevated fibroblast growth factor 23 is associated with prevalent anemia, change in hemoglobin over time, and development of anemia. Future studies are needed to elucidate the mechanisms for these associations.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.03950417","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T20:20:22Z","timestamp":1502137222000},"page":"1795-1803","source":"Crossref","is-referenced-by-count":68,"title":["Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study"],"prefix":"10.2215","volume":"12","author":[{"given":"Rupal","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hodakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungwha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ricardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sondheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Dobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Kusek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Isakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CRIC Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,10,9]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD.","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0735-1097(01)01470-X","article-title":"Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.","volume":"38","author":"Al-Ahmad","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.amjcard.2014.10.041","article-title":"Anemia and reduced kidney function as risk factors for new onset of atrial fibrillation (from the Ibaraki prefectural health study).","volume":"115","author":"Xu","year":"2015","journal-title":"Am J Cardiol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin.","volume":"34","author":"Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-6386(96)90130-4","article-title":"The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease.","volume":"28","author":"Foley","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","article-title":"Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia.","volume":"17","author":"Eriksson","year":"2016","journal-title":"BMC Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1185\/030079907X242502","article-title":"Association of anemia correction with health related quality of life in patients not on dialysis.","volume":"23","author":"Alexander","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"e0128994","DOI":"10.1371\/journal.pone.0128994","article-title":"Relation between red cell distribution width and fibroblast growth factor 23 cleaving in patients with chronic kidney disease and heart failure.","volume":"10","author":"van Breda","year":"2015","journal-title":"PLoS One"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"e3049","DOI":"10.1097\/MD.0000000000003049","article-title":"High fibroblast growth factor 23 levels associated with low hemoglobin levels in patients with chronic kidney sisease stages 3 and 4.","volume":"95","author":"Tsai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2009.551","article-title":"Vitamin D deficiency and anemia in early chronic kidney disease.","volume":"77","author":"Patel","year":"2010","journal-title":"Kidney Int"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/jbmr.1608","article-title":"Absence of sclerostin adversely affects B-cell survival.","volume":"27","author":"Cain","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/jbmr.1672","article-title":"Sclerostin: A new mediator of crosstalk between the skeletal and immune systems.","volume":"27","author":"Horowitz","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","article-title":"FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.","volume":"289","author":"Coe","year":"2014","journal-title":"J Biol Chem"},{"issue":"Suppl 2","key":"B15-20230813","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1097\/01.ASN.0000070149.78399.CE","article-title":"The Chronic Renal Insufficiency Cohort (CRIC) study: Design and methods.","volume":"14","author":"Feldman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study.","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD.","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2215\/CJN.00070109","article-title":"Chronic Renal Insufficiency Cohort (CRIC) study: Baseline characteristics and associations with kidney function.","volume":"4","author":"Lash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/ndt\/gfv037","article-title":"Longitudinal changes in hematocrit in hypertensive chronic kidney disease: Results from the African-American Study of Kidney Disease and Hypertension (AASK).","volume":"30","author":"Chen","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1681\/ASN.2012070713","article-title":"Mineral metabolites and CKD progression in African Americans.","volume":"24","author":"Scialla","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia.","volume":"372","author":"Camaschella","year":"2015","journal-title":"N Engl J Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease.","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.mayocp.2012.07.020","article-title":"Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure.","volume":"87","author":"Leshem-Rubinow","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ajh.2007.53","article-title":"Effects of the renin-angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.","volume":"21","author":"Inoue","year":"2008","journal-title":"Am J Hypertens"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ki.1996.398","article-title":"Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients.","volume":"50","author":"Gossmann","year":"1996","journal-title":"Kidney Int"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy.","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD.","volume":"126","author":"Rossaint","year":"2016","journal-title":"J Clin Invest"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","article-title":"Ironing out the cross talk between FGF23 and inflammation.","volume":"312","author":"David","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease.","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1681\/ASN.2013040355","article-title":"Suppression of iron-regulatory hepcidin by vitamin D.","volume":"25","author":"Bacchetta","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0301-472X(02)00789-0","article-title":"Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation.","volume":"30","author":"Alon","year":"2002","journal-title":"Exp Hematol"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1172\/JCI107651","article-title":"Bone marrow erythropoiesis in the anemia of infection, inflammation, and malignancy.","volume":"53","author":"Zucker","year":"1974","journal-title":"J Clin Invest"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000440968","article-title":"Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency.","volume":"131","author":"Iguchi","year":"2015","journal-title":"Nephron"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1687-9856-2012-27","article-title":"FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: A supplementation study.","volume":"2012","author":"Braithwaite","year":"2012","journal-title":"Int J Pediatr Endocrinol"},{"key":"B38-20230813","article-title":"Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal FGF23 levels of maintenance hemodialysis patients [published online ahead of print August 25, 2016].","author":"Yamashita","journal-title":"Nephrology (Carlton)"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease.","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-terminal FGF23 measurements.","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/ki.1993.383","article-title":"Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin.","volume":"44","author":"Fellner","year":"1993","journal-title":"Kidney Int"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrneph.2013.21","article-title":"Anaemia management and mortality risk in chronic kidney disease.","volume":"9","author":"H\u00f6rl","year":"2013","journal-title":"Nat Rev Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201711000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:06Z","timestamp":1786369026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201711000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,9]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.03950417","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,9]]}}}